Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,182.90

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,925.00 2
Food and Beverage $257.90 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $1,925.00 2
Janssen Biotech, Inc. $148.79 2
Janssen Research & Development, LLC $59.11 1
LEO Pharma Inc. $50.00 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1003852427?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $2,182.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $825.0010/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141227916 CMS
Janssen Research & Development, LLC $59.1103/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077588397 CMS
Janssen Biotech, Inc. $130.0103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779211 CMS
LEO Pharma Inc. $50.0003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152637479 CMS
Janssen Biotech, Inc. $18.7802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779183 CMS
Incyte Corporation $1,100.0001/31/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141304293 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $10,208.90 12/17/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843377
Principal investigator 1 Amgen Inc. $38.72 12/10/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study of the Efficacy and Safety of Apremilast CC-10004 in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp STYLE No dispute reported 06/30/2026 675788083
Principal investigator 1 Bausch Health US, LLC $3,717.00 12/09/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684366645
Principal investigator 1 AbbVie, Inc. $3,795.65 12/05/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M16-833 No dispute reported 06/30/2026 671843369
Principal investigator 1 Janssen Research & Development, LLC $8,445.00 11/18/2019 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 654242393
Principal investigator 1 Bausch Health US, LLC $1,690.00 11/09/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684366049
Principal investigator 1 AbbVie, Inc. $2,715.60 11/05/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M16-833 No dispute reported 06/30/2026 671843373
Principal investigator 1 Bausch Health US, LLC $2,258.50 11/04/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684365763
Principal investigator 1 Bausch Health US, LLC $3,430.00 11/04/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684365767
Principal investigator 1 AbbVie, Inc. $2,150.20 10/22/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843375
Principal investigator 1 Bausch Health US, LLC $3,663.00 10/09/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684365605
Recipient Eli Lilly and Company $15,969.00 10/08/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654284713
Principal investigator 1 Aclaris Therapeutics, Inc. $13,500.00 09/26/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700990243
Principal investigator 1 Aclaris Therapeutics, Inc. $3,312.00 09/26/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700990245
Principal investigator 1 AbbVie, Inc. $12,468.30 09/25/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843371
Principal investigator 1 Bausch Health US, LLC $7,844.00 09/16/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684365267
Principal investigator 1 AbbVie, Inc. $3,237.00 08/29/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843367
Principal investigator 1 Aclaris Therapeutics, Inc. $950.00 08/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989949
Principal investigator 1 Aclaris Therapeutics, Inc. $2,250.00 08/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989953
Principal investigator 1 Aclaris Therapeutics, Inc. $1,431.00 08/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989957
Principal investigator 1 Aclaris Therapeutics, Inc. $2,755.00 08/20/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989797
Principal investigator 1 Bausch Health US, LLC $10,614.00 08/06/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684364639
Principal investigator 1 Aclaris Therapeutics, Inc. $3,966.00 08/01/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989651
Principal investigator 1 Aclaris Therapeutics, Inc. $850.00 07/30/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989469
Principal investigator 1 Aclaris Therapeutics, Inc. $2,250.00 07/30/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989499
Principal investigator 1 Aclaris Therapeutics, Inc. $350.00 07/30/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989507
Principal investigator 1 AbbVie, Inc. $10,691.20 07/29/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843365
Principal investigator 1 Aclaris Therapeutics, Inc. $1,510.00 07/23/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700989287
Principal investigator 1 Aclaris Therapeutics, Inc. $3,155.00 07/23/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989291
Principal investigator 1 Bausch Health US, LLC $1,644.00 07/08/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684364261
Principal investigator 1 Bausch Health US, LLC $8,986.50 07/08/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684364265
Principal investigator 1 AbbVie, Inc. $1,618.50 06/27/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843363
Principal investigator 1 Aclaris Therapeutics, Inc. $6,124.00 06/25/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989229
Principal investigator 1 Eli Lilly and Company $1,494.46 06/25/2019 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654288527
Principal investigator 1 Aclaris Therapeutics, Inc. $2,150.00 06/24/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700989133
Principal investigator 1 Aclaris Therapeutics, Inc. $4,500.00 06/20/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989108
Principal investigator 1 Aclaris Therapeutics, Inc. $1,400.00 06/20/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989111
Recipient Eli Lilly and Company $4.75 06/10/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654284167
Principal investigator 1 Aclaris Therapeutics, Inc. $2,020.00 05/30/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700988755
Principal investigator 1 AbbVie, Inc. $2,150.20 05/29/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843361
Principal investigator 1 Aclaris Therapeutics, Inc. $100.00 05/28/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988557
Principal investigator 1 Aclaris Therapeutics, Inc. $890.00 05/28/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700988561
Principal investigator 1 Aclaris Therapeutics, Inc. $885.00 05/28/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988565
Principal investigator 1 Janssen Research & Development, LLC $5,190.00 05/24/2019 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 654242391
Principal investigator 1 Aclaris Therapeutics, Inc. $16,300.00 05/23/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988389
Principal investigator 1 Bausch Health US, LLC $1,902.00 05/17/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 684363595
Principal investigator 1 Aclaris Therapeutics, Inc. $975.00 04/30/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700988249
Principal investigator 1 AbbVie, Inc. $12,355.20 04/29/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843359
Principal investigator 1 Aclaris Therapeutics, Inc. $4,115.00 04/25/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988113
Principal investigator 1 Aclaris Therapeutics, Inc. $11,951.00 04/25/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988117
Principal investigator 1 Celgene Corporation $1,724.52 03/29/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) No dispute reported 06/30/2026 675418031
Principal investigator 1 AbbVie, Inc. $17,006.60 03/28/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
M15-997 No dispute reported 06/30/2026 671843379
Principal investigator 1 Celgene Corporation $113,194.30 03/25/2019 Non-covered Recipient Entity
Minnesota Clinical Study Center
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) No dispute reported 06/30/2026 675418029
Principal investigator 1 Janssen Research & Development, LLC $4,970.00 03/21/2019 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 654242389
Principal investigator 1 Aclaris Therapeutics, Inc. $15,030.00 03/19/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987561
Principal investigator 1 Aclaris Therapeutics, Inc. $3,035.00 03/19/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987707
Principal investigator 1 Novartis Pharmaceuticals Corporation $63,127.88 03/15/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 641813759
Principal investigator 1 Aclaris Therapeutics, Inc. $2,000.00 03/07/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700987485
Principal investigator 1 Aclaris Therapeutics, Inc. $16,073.00 03/05/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987243
Principal investigator 1 Aclaris Therapeutics, Inc. $4,820.00 03/05/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987407
Principal investigator 1 Aclaris Therapeutics, Inc. $2,500.00 03/05/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700987411
Principal investigator 1 Aclaris Therapeutics, Inc. $975.00 03/04/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700987098
Principal investigator 1 Aclaris Therapeutics, Inc. $1,400.00 02/26/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986967
Principal investigator 1 Aclaris Therapeutics, Inc. $5,000.00 02/26/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987021
Principal investigator 1 Aclaris Therapeutics, Inc. $1,600.00 02/07/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700986877
Principal investigator 1 Merck Sharp & Dohme Corporation $6,681.40 01/31/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010 No dispute reported 06/30/2026 691370387
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,346.59 01/23/2019 Non-covered Recipient Entity
Associated Skin Care Specialists - Minnesota Clinical Study Center
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 639760137
Principal investigator 1 Aclaris Therapeutics, Inc. $16,831.00 01/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986511
Principal investigator 1 Aclaris Therapeutics, Inc. $3,795.00 01/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986535
Principal investigator 1 Aclaris Therapeutics, Inc. $5,945.00 01/22/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986545
Principal investigator 1 Novartis Pharmaceuticals Corporation $535,894.32 01/07/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 641813761
Principal investigator 1 Aclaris Therapeutics, Inc. $13,071.00 01/03/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986327
Principal investigator 1 Aclaris Therapeutics, Inc. $4,185.00 01/03/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986391
Principal investigator 1 Aclaris Therapeutics, Inc. $1,450.00 01/02/2019 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700986175